A hybrid approach reveals the allosteric regulation of GTP cyclohydrolase I

Rebecca Ebenhoch(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Markus Zeeb(Boehringer Ingelheim (Germany)), Lisa Weixler(University Hospital Bonn), Martin Rübbelke(Boehringer Ingelheim (Germany)), Janet Vonck(Max Planck Institute of Biophysics), Simone Prinz(Max Planck Institute of Biophysics), Susann Kaltwasser(Max Planck Institute of Biophysics), Robert Meinecke(Boehringer Ingelheim (Germany)), Margit Bauer(Boehringer Ingelheim (Germany)), D.J. Reinert(Boehringer Ingelheim (Germany)), Deryck J. Mills(Max Planck Institute of Biophysics)
Proceedings of the National Academy of Sciences
November 23, 2020
10.1073/pnas.2013473117
Cited by 17

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285